XRAY DENTSPLY SIRONA Inc.

XRAY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Dentsply Sirona, Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Dentsply Sirona, Inc. (“Dentsply Sirona”) (NASDAQ: XRAY) violated federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/XRAY-Info-Request-Form-1707. There is no cost or obligation to you.

On August 9, 2017, Dentsply revealed second quarter 2017 earnings that were below expectations, and announced an SEC investigation “concerning the Company’s accounting and disclosures, including its accounting and disclosures relating to transactions with a significant distributor of the Company.” Following this news, Dentsply stock fell 8.44% to close at $56.23 per share on August 9, 2017. Then on October 2, 2017, Dentsply Sirona filed a Form 8-K announcing that the Company’s CEO, Executive Chairman, and COO all had tendered their respective resignations.

To learn more about the investigation of Dentsply Sirona contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/XRAY-Info-Request-Form-1707.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
04/10/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DENTSPLY SIRONA Inc.

Dentsply Sirona Inc.: Update to credit analysis

Our credit view of this issuer reflects its moderate financial leverage and its strong market position in the dental device industry, against its high reliance on distributors.

Dentsply Sirona Inc: 2 directors

Two Directors at Dentsply Sirona Inc bought 20,000 shares at between 12.445USD and 12.480USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ove...

 PRESS RELEASE

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleare...

First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This milestone follows the completion of a clinical trial2 validating the system’s significant potential across multiple dental specialties. The trial highlighted this first-of-its-kind technology’s applicability in endodontics, periodontics, TMJ, tooth extraction, and ort...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 7, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch